登录 | 注册    关注公众号  
搜索
 > 【DDR1】

DDR1信息

英文名称:Discoidin domain receptor 1
中文名称:盘状结构域受体-1
靶点别称:Epithelial discoidin domain-containing receptor 1,Epithelial discoidin domain receptor 1,CD167 antigen-like family member A,Cell adhesion kinase,Discoidin receptor tyrosine kinase,HGK2,Mammary carcinoma kinase 10,MCK-10,Protein-tyrosine kinase 3A,Protein-tyrosine kinase RTK-6,TRK E,Tyrosine kinase DDR,Tyrosine-protein kinase CAK,CD167a,CD167 Antigen-Like Family Member A,TRKE,RTK6,PTK3A Protein Tyrosine Kinase 3A,PTK3A,NTRK4,Neurotrophic Tyrosine Kinase, Receptor, Type 4,Neuroepithelial Tyrosine
上市药物数量:0
临床药物数量:2
最高研发阶段:临床一期

DDR1 分子别名

CD167a

DDR1 分子背景

Discoidin domain receptor 1 (DDR1) is a member of DDRs, which are members of the receptor tyrosine kinase (RTK). Upon collagen binding, DDR1 undergoes tyrosine autophosphorylation, which consequently triggers downstream genetic and cellular pathways and plays critical roles in the regulation of cellular morphogenesis, differentiation, proliferation, adhesion, migration, and invasion. Research shows that DDR1 is closely related to various human diseases including cancer, fibrosis, atherosclerosis, and other inflammatory disorders. New generation DDR1 inhibitors targeting the allosteric sites outside of the canonical ATP-binding pocket or extracellular domain (allosteric inhibitors) may offer a new opportunity for selective DDR1 inhibition therapy development.

DDR1 前沿进展

DDR1临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
AVI-4015 AVI-4015 临床一期 Avixgen 干眼综合征 详情
AGX-0073 AGX-0073 临床一期 上海翱健生物科技有限公司 实体瘤 详情
ICP-033 ICP-033 临床一期 北京诺诚健华医药科技有限公司 实体瘤 详情
APL-102 APL-102; CBT-102 临床一期 Apollomics 实体瘤 详情

消息提示

请输入您的联系方式,再点击提交!

确定